Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Tumorigenesis is characterised by changes in transcriptional control. Extensive transcript expression data have been acquired over the last decade and used to classify prostate cancers. Prostate cancer is, however, a heterogeneous multifocal cancer and this poses challenges in identifying robust transcript biomarkers. METHODS: In this study, we have undertaken a meta-analysis of publicly available transcriptomic data spanning datasets and technologies from the last decade and encompassing laser capture microdissected and macrodissected sample sets. RESULTS: We identified a 33 gene signature that can discriminate between benign tissue controls and localised prostate cancers irrespective of detection platform or dissection status. These genes were significantly overexpressed in localised prostate cancer versus benign tissue in at least three datasets within the Oncomine Compendium of Expression Array Data. In addition, they were also overexpressed in a recent exon-array dataset as well a prostate cancer RNA-seq dataset generated as part of the The Cancer Genomics Atlas (TCGA) initiative. Biologically, glycosylation was the single enriched process associated with this 33 gene signature, encompassing four glycosylating enzymes. We went on to evaluate the performance of this signature against three individual markers of prostate cancer, v-ets avian erythroblastosis virus E26 oncogene homolog (ERG) expression, prostate specific antigen (PSA) expression and androgen receptor (AR) expression in an additional independent dataset. Our signature had greater discriminatory power than these markers both for localised cancer and metastatic disease relative to benign tissue, or in the case of metastasis, also localised prostate cancer. CONCLUSION: In conclusion, robust transcript biomarkers are present within datasets assembled over many years and cohorts and our study provides both examples and a strategy for refining and comparing datasets to obtain additional markers as more data are generated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Mathematical Theory of Communication
Shannon, C. E. (1948) · Bell System Technical Journal · doi:10.1002/j.1538-7305.1948.tb01338.x · Cited by 88,486
Hierarchical Grouping to Optimize an Objective Function
Ward, J. H. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500845 · Cited by 20,598 · cited 13×
“To determine the best clustering method and branch length thresholds to apply to our analysis we clustered our 4662 reporter prostate tumour progression signature (Additional file 2: Table S1) using single, average, complete, Ward’s1 minimum variance method and mcquitty2 agglomerative hierarchical clustering methods a…”
MethodInfluentialRidge regression: Biased estimation for nonorthogonal problems
Hoerl, A. E., & Kennard, R. W. (1970) · Technometrics · doi:10.1080/00401706.1970.10488634 · Cited by 9,648
Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer
Tomlins, S. A., Rhodes, D. R., Perner, S., Dhanasekaran, S. M., Mehra, R., Sun, X.-W., Varambally, S., Cao, X., Tchinda, J., Kuefer, R., et al. (2005) · Science · doi:10.1126/science.1117679 · Cited by 3,846
Integrative Genomic Profiling of Human Prostate Cancer
Taylor, B. S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B. S., Arora, V. K., Kaushik, P., Cerami, E., Reva, B., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.05.026 · Cited by 3,701 · cited 1×
“, and also The Cancer Genome Atlas (TCGA) data recently generated using high-throughput transcript sequencing of prostate cancers [24] (data generated by the data generated by the TCGA Research Network: http:// cancergenome.”
MethodONCOMINE: A Cancer Microarray Database and Integrated Data-Mining Platform
Rhodes, D. R., Yu, J., Shanker, K., Deshpande, N., Varambally, R., Ghosh, D., Barrette, T., Pander, A., & Chinnaiyan, A. M. (2004) · Neoplasia · doi:10.1016/s1476-5586(04)80047-2 · Cited by 3,612
Ridge Regression: Applications to Nonorthogonal Problems
Hoerl, A. E., & Kennard, R. W. (1970) · Technometrics · doi:10.1080/00401706.1970.10488635 · Cited by 2,956
The mutational landscape of lethal castration-resistant prostate cancer
Grasso, C. S., Wu, Y.-M., Robinson, D. R., Cao, X., Dhanasekaran, S. M., Khan, A. P., Quist, M. J., Jing, X., Lonigro, R. J., Brenner, J. C., et al. (2012) · Nature · doi:10.1038/nature11125 · Cited by 2,517 · cited 1×
“, and consisting of benign tissue, localised prostate cancer and metastatic cases [43].”
BackgroundA molecular signature of metastasis in primary solid tumors
Ramaswamy, S., Ross, K. N., Lander, E. S., & Golub, T. R. (2003) · Nature Genetics · doi:10.1038/ng1060 · Cited by 2,449 · cited 18×
“Ramaswamy S, Ross KN, Lander ES, Golub TR: A molecular signature of metastasis in primary solid tumors.”
BackgroundMethodInfluentialIn vivo amplification of the androgen receptor gene and progression of human prostate cancer
Visakorpi, T., Hyytinen, E., Koivisto, P., Tanner, M., Keinänen, R., Palmberg, C., Palotie, A., Tammela, T., Isola, J., & Kallioniemi, O.-P. (1995) · Nature Genetics · doi:10.1038/ng0495-401 · Cited by 1,484
Cited by
Wang, A., Shen, J., Rodriguez, A. A., Saunders, E. J., Chen, F., Janivara, R., Darst, B. F., Sheng, X., Xu, Y., Chou, A., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01534-4 · Cited by 190
“…in prostate cancer risk, expression of SIM2 , a transcription factor, has been shown to discriminate prostate cancer and noncancerous tumor tissue 17 and to be associated with poorer survival 18 , while PIM1 is a serine/threonine kinase overexpressed in prostate cancer 19 , shown to modulate…”
BackgroundGlycans as Biomarkers in Prostate Cancer
Scott, E., & Munkley, J. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061389 · Cited by 143
The role of glycans in the development and progression of prostate cancer
Munkley, J., Mills, I. G., & Elliott, D. J. (2016) · Nature Reviews Urology · doi:10.1038/nrurol.2016.65 · Cited by 133
Self-citationBarfeld, S. J., Urbanucci, A., Itkonen, H. M., Fazli, L., Hicks, J. L., Thiede, B., Rennie, P. S., Yegnasubramanian, S., Marzo, A. M. D., & Mills, I. G. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.006 · Cited by 126
“The AR is a ligand-activated transcription factor that controls key cellular processes including anabolic metabolism and cell cycle control (Barfeld et al., 2014b; Massie et al., 2011).”
BackgroundSelf-citationMunkley, J., Oltean, S., Vodák, D., Wilson, B. T., Livermore, K. E., Zhou, Y., Star, E., Floros, V. I., Johannessen, B., Knight, B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.6024 · Cited by 98
“A recent meta-analysis of clinical PCa gene expression data identified a novel discriminatory signature enriched for 4 glycosylating enzymes ST6GalNAc1: glucosaminyl (N-acetyl) transferase 1, core 2 (GCNT1), UDP N-acetylglucosamine pyrophosphorylase 1 (UAP1) and beta-1,3-glucuronyltransferase 1 (B3GAT1) [25].”
BackgroundSelf-citation
Metadata
- Authors
- Barfeld, S. J., East, P., Zuber, V., & Mills, I. G.
- Affiliations
- Oslo University Hospital (NO)
- Corresponding author
- Barfeld, Stefan J
- Mills, Ian G
- Venue
- BMC Medical Genomics
- Published
- 2014-12
- Volume
- 7
- Issue
- 1
- Pages
- 513-513
- ISSN
- 1755-8794 (ISSN-L)
- PMC
- PMC4351903
- OpenAlex
- W2034829050
- Cited by
- 47
- References
- 49
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 2 · 2022: 6 · 2021: 4 · 2020: 7 · 2019: 6 · 2018: 4 · 2017: 5 · 2016: 5 · 2015: 3
- FWCI
- 0.74
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 30 d)
- Locations
- BMC Medical Genomics (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion, other-oa)
- NORA - Norwegian Open Research Archives (submittedVersion, cc-by)
- Funders
- Kreftforeningen
- European Molecular Biology Laboratory
- Cancer Research UK
- University of Cambridge
- Universitetet i Oslo
- Norges Forskningsråd
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- prostate cancer, gene expression signatures, glycosylation, localized prostate cancer, metastatic prostate cancer, ERG, prostate-specific antigen, androgen receptor, tumor heterogeneity
- MeSH terms
- Glycosylation, Humans, Male, Neoplasm Proteins, Prostatic Neoplasms, Gene Expression Regulation, Neoplastic, Gene Expression Regulation, Developmental, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. https://app.cochat.ai/papers/10.1186/s12920-014-0074-9
- The paper
- Barfeld, S. J., East, P., Zuber, V., & Mills, I. G. (2014). Meta-analysis of prostate cancer gene expression data identifies a novel discriminatory signature enriched for glycosylating enzymes. BMC Medical Genomics. https://doi.org/10.1186/s12920-014-0074-9
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.